1. Home
  2. VEL vs CGEM Comparison

VEL vs CGEM Comparison

Compare VEL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Velocity Financial Inc.

VEL

Velocity Financial Inc.

N/A

Current Price

$18.26

Market Cap

768.3M

Sector

Finance

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$14.31

Market Cap

780.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VEL
CGEM
Founded
2004
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
768.3M
780.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
VEL
CGEM
Price
$18.26
$14.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$22.00
$29.89
AVG Volume (30 Days)
88.9K
771.8K
Earning Date
01-01-0001
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
25.66
N/A
EPS
1.86
N/A
Revenue
N/A
N/A
Revenue This Year
$5.75
N/A
Revenue Next Year
$27.31
N/A
P/E Ratio
$9.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.12
$5.68
52 Week High
$21.40
$16.74

Technical Indicators

Market Signals
Indicator
VEL
CGEM
Relative Strength Index (RSI) 33.60 52.61
Support Level $17.87 $6.65
Resistance Level $19.23 $16.74
Average True Range (ATR) 0.39 1.01
MACD -0.07 -0.10
Stochastic Oscillator 34.15 25.77

Price Performance

Historical Comparison
VEL
CGEM

About VEL Velocity Financial Inc.

Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: